周四，Cronos Group Inc（纳斯达克股票代码：CRON）报告第四季度销售额为3030万美元，高于上一季度的2392万美元，但未达到市场预期的3495万美元。同比增长主要由加拿大市场的大麻花和提取物销售增加，以及以色列和其他国家的大麻花销售增加所推动。Cronos GrowCo在2024年第四季度贡献了210万美元的大麻花销售额。这家大麻素公司报告每股收益为0.11美元，相较于上一季度每股亏损0.19美元。公司报告毛利润为1080万美元，高于上一季度的191万美元，主要由于销售增加和生产成本改善。毛利润受到了180万美元的积极影响，这与Cronos GrowCo交易的购置会计最终确定有关，其导致从Cronos GrowCo获取的库存的公允价值减少以及之前记录在销售成本中的库存阶梯上升减少。此外，调整后的毛利润为900万美元，比2023年第四季度改善了710万美元。调整后的EBITDA亏损达到720万美元，改善了760万美元。主席、总裁兼CEO Mike Gorenstein表示：“Cronos有很好的定位能够把握未来的机会，为我们的股东创造长期价值。展望2025年，我们将继续保持这种势头，巩固我们的市场领导地位，并推出在全球范围内深受消费者欢迎的创新产品。”他补充道：“我们的战略投资，如Cronos GrowCo，增强了我们的种植能力，确保了高质量大麻的持续供应，并改善了毛利率，同时，我们的研发突破树立了行业新标准。”

以上内容来自Benzinga Earnings专栏，原文如下：

On Thursday, Cronos Group Inc (NASDAQ:CRON) reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.

The increase year-over-year was primarily driven by higher cannabis flower and extract sales in the Canadian market and higher cannabis flower sales in Israel and other countries.

Cronos GrowCo contributed $2.1 million of cannabis flower sales in Q4 2024.

The cannabinoid company reported earnings of 11 cents compared to a loss of 19 cents.

Also Next: Cronos CEO Mike Gorenstein Says He’s Optimistic About Trump’s Impact On Cannabis

The company reported a gross profit of $10.8 million, up from $1.91 million, primarily due to higher sales and production cost improvements. Gross profit was positively impacted by $1.8 million in the quarter in connection with the finalization of the purchase accounting for the Cronos GrowCo Transaction, which resulted in a reduction of the fair value of inventory acquired from Cronos GrowCo and the corresponding inventory step-up previously recorded into the cost of sales.

• Adjusted gross profit of $9.0 million, improved by $7.1 million from Q4 2023.

Adjusted EBITDA loss reached $7.2 million, an improvement of $7.6 million.

“Cronos is well-positioned to capitalize on future opportunities and drive long-term value for our shareholders. As we look ahead to 2025, we remain focused on sustaining this momentum, strengthening our market leadership, and delivering innovative products that resonate with consumers worldwide,” said Mike Gorenstein, chairman, president and CEO of Cronos.

“Our strategic investments, such as Cronos GrowCo, have enhanced our cultivation capabilities, ensuring a consistent supply of high-quality cannabis at scale with an improved gross margin profile, while our R&D breakthroughs have set new industry standards,” Gorenstein added.

Price Action: CRON stock is up 7.87% at $1.9 at the last check Thursday.

Read Next:

• Payoneer Q4: 17% Revenue Growth, $22.5 Billion In Transactions, B2B Payments Up 37%, Revenue Target Surges

Photo: Shutterstock